Quick Answer
Aligos Therapeutics, Inc. reported Diluted EPS of $2.45 per share (loss) for fiscal year 2025.
Aligos Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.45 | +88.3% |
| 2024 | -$20.94 | +38.8% |
| 2023 | -$34.20 | -1420.0% |
| 2022 | -$2.25 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.04 | +1.0% | -98.7% |
| June 30, 2025 | -$1.53 | -288.9% | +27.5% |
| March 31, 2025 | -$2.11 | +62.2% | +31.3% |
| September 30, 2024 | -$3.07 | +70.4% | -479.0% |
| June 30, 2024 | $0.81 | +288.4% | +114.5% |
| March 31, 2024 | -$5.58 | -952.8% | +46.2% |
| September 30, 2023 | -$10.37 | -2256.8% | -2311.6% |
| June 30, 2023 | -$0.43 | +8.5% | +18.9% |
- Aligos Therapeutics, Inc. showed an increase of +88.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Aligos Therapeutics, Inc.’s diluted eps has declined by 8.9% (from $2.25 per share (loss) to $2.45 per share (loss)).
- The most recent figure is from Aligos Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: